INT273547

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.21
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Orm1) extracellular space (Orm1) extracellular region (Orm1)
Anatomy Link Frequency
plasma 2
Orm1 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 5 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Piles 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
abdominal pain 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Aneuploidy 1 81.92 Quite High
Myeloid Leukemia 64 65.96 Quite High
Disease 2 62.92 Quite High
Leukemia 6 50.00 Quite Low
Chromosome Aberrations 2 33.92 Quite Low
Philadelphia Chromosome 11 5.00 Very Low Very Low Very Low
Toxicity 8 5.00 Very Low Very Low Very Low
Pressure And Volume Under Development 8 5.00 Very Low Very Low Very Low
Blast Crisis 8 5.00 Very Low Very Low Very Low
Apoptosis 7 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Other mechanisms of resistance to imatinib include alteration of the balance favoring the active state of ABL kinase, shifting the equilibrium between active and inactive states;15 a change in the conformation of the BCR-ABL protein, preventing imatinib from directly binding to its binding site;16 amplification of the BCR-ABL gene, leading to over-expression of BCR-ABL protein, as detected by FISH;13,16 or over-expression of the P-glycoprotein efflux pump, for which imatinib is the substrate.17,18 Additional mechanisms include the binding of the A1 acid glycoprotein (AGP) to imatinib in plasma, reducing its intracellular concentrations,19 or a less understood mechanism, the inhibition of ABCG2 protein functionality by imatinib.20
Negative_regulation (reducing) of acid glycoprotein Binding (binding) of in plasma
1) Confidence 0.01 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697539 Disease Relevance 0.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox